# US 2026/0216184 A1 · Use of compound 1 in treatment or prevention of renal fibrosis and other diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216184 A1
- Document ID: US20260216184A1
- Status: Published application
- Kind: A1
- Application number: 19/147,302
- Filed: 2024-01-12
- Published: 2026-07-30
- Earliest claimed: 2023-01-13
- Assignees: Shenzhen Newdel Biotech Co., Ltd.
- Applicants: Shenzhen Newdel Biotech Co., Ltd.
- Inventors: Xun HE; Feng JIN; Yuhan GUO; Tianyuan ZHANG; Zhenwei LI; Wei HU
- Web page: https://patentgrep.com/patent/US20260216184A1

## CPC

- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to use of N-(3-chloro-5-(trifluoromethyl)phenyl)-3-((6-(4-hydroxypiperidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)ethynyl)-2-methylbenzamide (also referred to herein as compound 1) or a pharmaceutically acceptable salt thereof in the treatment or prevention of renal fibrosis and other diseases.

## Claims

### Claim 1

Use of compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing renal fibrosis, wherein compound 1 has the following structure:

### Claim 2

Use of compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease mediated by DDR1 or that may be controlled by inhibiting DDR1, wherein compound 1 has the following structure:

### Claim 3

Use of compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease mediated by DDR2 or that may be controlled by inhibiting DDR2, wherein compound 1 has the following structure:

### Claim 4

Use of compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease mediated by EPHA6 or that may be controlled by inhibiting EPHA6, wherein compound 1 has the following structure:

### Claim 5

Use of compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease mediated by CSF1R or that may be controlled by inhibiting CSF1R, wherein compound 1 has the following structure:
